Table 3 Comparison of Proseek® values obtained from women with late stage ovarian cancer versus benign disease
From: A multiplex platform for the identification of ovarian cancer biomarkers
Protein | Late versus benign | |||
|---|---|---|---|---|
AUC (95% CI) | Rank | Sensitivity at 95% specificity (95% CI) | Rank | |
HE4 | 1 (0.98, 1) | 1 | 0.99 (0.91, 1) | 2 |
CA.125 | 1 (0.97, 1) | 2 | 1 (0.89, 1) | 1 |
KLK6 | 0.95 (0.91, 0.99) | 3 | 0.88 (0.74, 0.97) | 3 |
MK | 0.95 (0.9, 0.99) | 4 | 0.79 (0.61, 0.96) | 4 |
hK11 | 0.93 (0.87, 0.97) | 5 | 0.7 (0.48, 0.91) | 6 |
FR.alpha | 0.91 (0.83, 0.98) | 6 | 0.75 (0.55, 0.93) | 5 |
IL.6 | 0.91 (0.82, 0.97) | 7 | 0.69 (0.44, 0.88) | 7 |
CSF.1 | 0.87 (0.75, 0.96) | 8 | 0.4 (0.12, 0.8) | 20 |
CXCL13 | 0.86 (0.77, 0.95) | 9 | 0.6 (0.32, 0.82) | 9 |
EZR | 0.86 (0.76, 0.93) | 10 | 0.63 (0.42, 0.83) | 8 |
PRSS8 | 0.86 (0.74, 0.94) | 11 | 0.56 (0.32, 0.81) | 12 |
FUR | 0.84 (0.74, 0.94) | 12 | 0.48 (0.27, 0.76) | 15 |
AM | 0.83 (0.71, 0.94) | 13 | 0.46 (0.22, 0.77) | 17 |
CXCL10 | 0.83 (0.73, 0.92) | 14 | 0.57 (0.32, 0.8) | 10 |
TNF.R1 | 0.8 (0.67, 0.93) | 15 | 0.36 (0.09, 0.75) | 23 |
CSTB | 0.79 (0.64, 0.92) | 16 | 0.36 (0.11, 0.76) | 22 |
ILT.3 | 0.79 (0.65, 0.91) | 17 | 0.32 (0.09, 0.7) | 26 |
CXCL9 | 0.78 (0.65, 0.9) | 18 | 0.48 (0.21, 0.74) | 16 |
VEGF.A | 0.77 (0.65, 0.88) | 19 | 0.52 (0.26, 0.71) | 14 |
IL.7 | 0.76 (0.62, 0.89) | 20 | 0.38 (0.14, 0.64) | 21 |
ITGA1 | 0.76 (0.62, 0.88) | 21 | 0.57 (0.38, 0.75) | 11 |
ErbB4.HER4 | 0.75 (0.62, 0.86) | 22 | 0.53 (0.32, 0.7) | 13 |
IL.8 | 0.74 (0.56, 0.9) | 23 | 0.2 (0.01, 0.66) | 50 |
MCP.1 | 0.74 (0.59, 0.89) | 24 | 0.22 (0.06, 0.57) | 43 |
U.PAR | 0.74 (0.57, 0.85) | 25 | 0.15 (0.03, 0.41) | 58 |